/
BDTX
$1.75+$0.04 (+2.34%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$98.0M
57M shares
52-week range
$1.60 – $4.94
4% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.36%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-10.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $70.0M |
| Cost of revenue | $44.0K | $47.0K | $0 | $0 | $0 | $437.0K | $0 | $325.0K |
| Gross profit | −$44.0K | −$47.0K | $0 | $0 | $0 | −$437.0K | $0 | $69.7M |
| Gross margin | — | — | — | — | — | — | — | 99.5% |
| R&D | $7.0M | $21.8M | $48.2M | $96.8M | $64.4M | $58.9M | $51.3M | $33.6M |
| Operating income | −$8.9M | −$8.9M | −$69.6M | −$126.9M | −$92.8M | −$86.5M | −$78.8M | $19.9M |
| EBITDA | −$8.9M | −$29.3M | −$66.7M | −$125.4M | −$90.7M | −$82.0M | −$69.3M | $22.7M |
| Net income | −$8.9M | −$35.3M | −$67.3M | −$125.6M | −$91.2M | −$82.4M | −$69.7M | $22.4M |
| Net margin | — | — | — | — | — | — | — | 32.0% |
| EPS (diluted) | -0.64 | -1.15 | -2.04 | -3.47 | -2.52 | -1.88 | -1.27 | 0.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-0.65 | $-0.81–$-0.11 | 7 |
| 2027 | $3M | $-1.00 | $-1.79–$-0.54 | 6 |
| 2028 | $12M | $-1.00 | $-1.52–$-0.55 | 7 |
| 2029 | $13M | $-1.26 | $-1.26–$-1.26 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$12.01
Price
$1.75
Implied upside
+586%
Peer comparison
Black Diamond Therapeutics, Inc. Common Stock
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
www.blackdiamondtherapeutics.com- Employees
- 21
- IPO / List date
- Jan 30, 2020
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds BDTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,643,747 | $3.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BDTX yet.
